Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance

Lenvatinib is a multitargeted tyrosine kinase inhibitor (TKI) that shows improved median progression-free survival (PFS) in patients with thyroid carcinomas. However, virtually all patients ultimately progress, indicating the need for a better understanding of the mechanisms of resistance. Here, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Husain Yar, Ge, James, Nagasaka, Misako, Aboukameel, Amro, Mpilla, Gabriel, Muqbil, Irfana, Szlaczky, Mark, Chaker, Mahmoud, Baloglu, Erkan, Landesman, Yosef, Mohammad, Ramzi M., Azmi, Asfar S., Sukari, Ammar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6982268/
https://www.ncbi.nlm.nih.gov/pubmed/31905765
http://dx.doi.org/10.3390/ijms21010237

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6982268/
https://www.ncbi.nlm.nih.gov/pubmed/31905765
http://dx.doi.org/10.3390/ijms21010237

Ejemplares similares